Article Sidebar

PDF
Date Published: 10/05/2024
Abstract Views: 135
Views PDF: 54
DOI: https://doi.org/10.51298/vmj.v538i2.9433
Issue
Vol. 538 No. 2 (2024)
Section
Các bài báo
How to Cite
Nguyễn , C. V., Tô, A. D., Nguyễn , C. H., & Đặng , T. V. A. (2024). SURVIVAL IN NEUROENDOCRINE CERVICAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY USING EP REGIMEN IN K HOSPITAL. Vietnam Medical Journal, 538(2). https://doi.org/10.51298/vmj.v538i2.9433

SURVIVAL IN NEUROENDOCRINE CERVICAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY USING EP REGIMEN IN K HOSPITAL

Chí Việt Nguyễn , Anh Dũng Tô, Công Hoàng Nguyễn , Thị Vân Anh Đặng

Main Article Content

Abstract

Objective: To analyze patterns of the overall survival and disease-free survival in women with neuroendocrine cervical cancer (NECC) undergoing concurrent chemoradiotherapy using EP regimen at K Hospital between 2018 and 2023. Methods: A retrospective study of patients with FIGO stage I-IVA NECC who were treated with concurrent chemoradiotherapy using EP regimen. Disease-free survival (DFS) and overall survival (OS) according to disease and clinical characteristics were analyzed using Kaplan-Meiee method. Results: Among 72 patients with NECC, with a medial follow-up of 25 months (ranging from 6.5 to 64.3 months), 5 patients (6.9%) experienced local recurrence, 34 patients (47,2%) had distant metastatic and 35 (48,6%) died. The medial overall survival was 31.9 months. OS-2years and OS-5years were observed at 61.7% and 45.5%, respectively. The medial DFS was 25.4 months, with DFS-2years and 5years were 54.9% and 44.2%, respectively. Conclusion: Neuroendocrine cervical cancer was an agrgressive disease with poor prognosis. Noteworthy occurrences of mortality and disease progression manifest within the initial two years following treatment initiation.

Article Details

Keywords

Concurrent chemoradiotherapy, Cervical cancer, Neuroendocrine carcinoma, EP regimen

References

1. Diệu, B., Ung thư cổ tử cung. Hướng dẫn chẩn đoán và điều trị một số bệnh ung thư thường gặp, 2016. Nhà xuất bản Y học: p. 308-318.
2. Hsu, H.C., et al., Surveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapy. Front Oncol, 2015. 5: p. 81.
3. Lee, S.W., et al., Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer, 2010. 20(3): p. 411-6.
4. Tempfer, C.B., et al., Neuroendocrine carcinoma of the cervix: a systematic review of the literature. BMC cancer, 2018. 18(1): p. 530-530.
5. Intaraphet, S., et al., Prognostic factors for small cell neuroendocrine carcinoma of the uterine cervix: an institutional experience. Int J Gynecol Cancer, 2014. 24(2): p. 272-9.
6. Al-Hiyasat, A.S., K.M. Barrieshi-Nusair, and M.A. Al-Omari, The radiographic outcomes of direct pulp-capping procedures performed by dental students: a retrospective study. J Am Dent Assoc, 2006. 137(12): p. 1699-705.
7. Cohen, J.G., et al., Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol, 2010. 203(4): p. 347.e1-6.
8. Zivanovic, O., et al., Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol, 2009. 112(3): p. 590-3.
9. Sodsanrat, K., N. Saeaib, and T. Liabsuetrakul, Comparison of Clinical Manifestations and Survival Outcomes between Neuroendocrine Tumor and Squamous Cell Carcinoma of the Uterine Cervix: Results from a Tertiary Center in Southern Thailand. J Med Assoc Thai, 2015. 98(8): p. 725-33.
10. Stecklein, S.R., et al., Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol, 2016. 143(3): p. 552-557.